Substituted Cyclopentanes for Glaucoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, particularly primary open-angle glaucoma, often fail to effectively reduce intraocular pressure, leading to potential vision loss, and existing ocular hypotensive agents may not adequately address the underlying causes of increased intraocular pressure.
Innovation Solution
Development of novel compounds represented by a specific structural formula, which can be administered topically to reduce intraocular pressure by enhancing aqueous humor outflow, thereby delaying or preventing the onset of glaucoma and associated vision loss.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing ocular hypotensive agents are used, then treatment for glaucoma is provided, but they fail to effectively reduce intraocular pressure
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of prostaglandin analogs through specific substitutions at positions 1, 2, and 3 of the cyclopentane ring. These structural parameter changes (introducing fluorine atoms, methyl groups, and various substituent patterns) enhance the compound's ability to activate FP receptors, thereby improving intraocular pressure reduction effectiveness while maintaining selective ocular action.
Solution Approach 2:
The patent employs composite material principles by creating hybrid molecular structures that combine the core prostanoic acid skeleton with specific cyclic substituents (cyclopentane rings with various attachments). This composite structural approach integrates multiple functional groups (carboxylic acid, ester, amide, hydroxymethyl, ether, thioether) to achieve both high FP receptor affinity and improved pharmacokinetic properties for effective glaucoma treatment.
2Reliability
If prostaglandins and prostamides are used as first line treatments, then glaucoma management is improved, but they may not adequately address the underlying causes of increased intraocular pressure
Solution Approach 1:
The patent applies the extraction principle by isolating and optimizing the specific FP receptor-active components of prostaglandins. By extracting the essential pharmacophore elements (cyclopentane ring with specific substituents at positions 1, 2, and 3) and removing less effective structural elements, the patent creates compounds with enhanced FP receptor selectivity and potency, directly addressing the underlying mechanism of aqueous humor outflow improvement.
Solution Approach 2:
The patent implements local quality by introducing specific substituents at particular positions of the prostanoic acid skeleton. The cyclopentane ring with targeted substitutions at positions 1, 2, and 3 creates localized structural features that enhance FP receptor binding affinity. This local structural optimization allows the compound to exert its hypotensive effect more effectively at the target site while maintaining overall molecular stability.
Data Source
AI summary
Disclosed herein are compounds having a formula:Therapeutic methods, medicaments, and compositions related thereto are also disclosed.